Pmv Pharmaceuticals Inc
$ 1.47
8.89%
14 Apr - close price
- Market Cap 71,995,000 USD
- Current Price $ 1.47
- High / Low $ 1.49 / 1.35
- Stock P/E N/A
- Book Value 1.96
- EPS -1.48
- Next Earning Report 2026-05-08
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.35 %
- ROE -0.55 %
- 52 Week High 1.88
- 52 Week Low 0.81
About
PMV Pharmaceuticals, Inc., a precision oncology company, is dedicated to the discovery and development of small molecule tumor agnostic therapies for p53 mutations in cancer. The company is headquartered in Cranbury, New Jersey.
Analyst Target Price
$4.75
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-05 | 2025-11-12 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-29 | 2023-11-09 | 2023-08-09 | 2023-05-10 |
| Reported EPS | -0.34 | -0.4 | -0.41 | -0.34 | -0.45 | -0.37 | -0.02 | -0.3 | -0.31 | -0.34 | -0.38 | -0.42 |
| Estimated EPS | -0.415 | -0.4 | -0.39 | -0.3833 | -0.38 | -0.35 | -0.35 | -0.36 | -0.39 | -0.45 | -0.47 | -0.46 |
| Surprise | 0.075 | 0 | -0.02 | 0.0433 | -0.07 | -0.02 | 0.33 | 0.06 | 0.08 | 0.11 | 0.09 | 0.04 |
| Surprise Percentage | 18.0723% | 0% | -5.1282% | 11.2966% | -18.4211% | -5.7143% | 94.2857% | 16.6667% | 20.5128% | 24.4444% | 19.1489% | 8.6957% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-08 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.4 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PMVP
2026-04-13 15:39:31
Evercore ISI has lowered its price target for PMV Pharmaceuticals (PMVP) from $16 to $4, while maintaining an Outperform rating on the shares. This adjustment reflects updated models within the firm's small-to-mid cap biotech coverage. PMV Pharmaceuticals recently reported its FY25 EPS and provided a cash runway update, indicating steady progress in its TP53-Driven Oncology rezatapopt trials.
2026-03-25 12:39:51
Insiders at PMV Pharmaceuticals sold US$152k worth of stock at an average price of US$1.06 over the past year. This move appears vindicated after the company's market worth decreased by US$9.1m due to an 11% stock drop. While the largest individual sale by Co-Founder David Mack was below the current trading price, insiders did not purchase any shares in the last year, and their overall ownership remains at a relatively low 3.4%.
2026-03-25 10:40:51
Insiders at PMV Pharmaceuticals sold US$152k worth of stock at an average price of US$1.06 over the past year. This move seems vindicated as the company's market worth recently decreased by 11% (US$9.1m). While insider selling isn't always a strong indicator, it suggests that those close to the company considered a lower price reasonable, especially since no insiders bought shares during the same period.
2026-03-10 09:51:31
PMV Pharmaceuticals' CFO, Michael Carulli, was granted an employee stock option for 240,000 shares of common stock with an exercise price of $0.00 per share. This grant vests in 48 equal monthly installments starting on April 5, 2026, over a four-year period. Following this transaction, Carulli directly holds 73,848 shares of common stock, including those acquired via the company's Employee Stock Purchase Plan.
2026-03-10 09:51:30
PMV Pharmaceuticals' General Counsel and COO, Robert Ticktin, was granted 319,270 employee stock options. These options, which have an exercise price of $1.53 per share, do not represent stock purchased on the open market but rather the right to acquire shares in the future. The award vests in 48 equal monthly installments starting April 3, 2026, over a four-year period.
2026-03-09 07:51:59
PMV Pharmaceuticals (NASDAQ:PMVP) reported quarterly earnings of ($0.34) per share, surpassing analyst estimates by $0.06. This positive news led to a 7.2% increase in the stock price. Institutional investors hold a significant portion of PMVP shares, and while analyst coverage is mixed, the company has a consensus "Hold" rating with an average price target of $5.00.
